Search

Relay Therapeutics Inc

Atvērts

SektorsVeselības aprūpe

19.76 1.7

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

18.59

Max

19.79

Galvenie mērījumi

By Trading Economics

Ienākumi

-10M

-84M

Pārdošana

-2.7M

350K

EPS

-0.41

Peļņas marža

-23,916.286

Darbinieki

202

EBITDA

-10M

-83M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+41.15% upside

Dividendes

By Acuity

Nākamie ieņēmumi

2026. g. 5. nov.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

437M

4.5B

Iepriekšējā atvēršanas cena

18.06

Iepriekšējā slēgšanas cena

19.76

Ziņu noskaņojums

By Acuity

50%

50%

147 / 340 Rangs Healthcare

Relay Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 21. aug. 21:01 UTC

Relay Therapeutics Inc is trading higher in after-market hours, up significantly since Friday's close and above its 20-day moving average.

2026. g. 20. aug. 20:02 UTC

Correlated Moves

Relay Therapeutics Inc shares are lower today, influenced by a decline in the broader Biotechnology sector and significant market volatility. Trading volume remains unusually high.

2026. g. 19. aug. 23:01 UTC

Relay Therapeutics Inc is trading higher in after-market hours, positioned near the upper end of its one-month range and above its 20-day moving average.

2026. g. 18. aug. 22:26 UTC

Relay Therapeutics Inc. shares traded lower after market hours, reflecting broader market pressure from rising bond yields and inflation concerns.

2026. g. 17. aug. 19:36 UTC

Social Media
News

Relay Therapeutics Inc is trading higher amid a Phase 3 trial for its breast cancer treatment and a $53 million investment from Baker Bros.

2026. g. 14. aug. 21:51 UTC

Social Media

Relay Therapeutics Inc is gaining in after-market trading, supported by social media discussions and a significant portfolio stake from Perceptive Advisors.

2026. g. 13. aug. 19:16 UTC

Correlated Moves

Relay Therapeutics Inc is trading lower, reflecting broader declines in the biotechnology sector amid fluctuations and rising initial jobless claims.

2026. g. 10. aug. 19:56 UTC

News
Social Media

Relay Therapeutics shares are higher after Citizens raised its price target to $26, citing confidence in the company's Phase 3 trials.

2026. g. 7. aug. 20:06 UTC

News
Correlated Moves
Social Media

Barclays raised its price target on Relay Therapeutics to $30.00, contributing to positive sentiment amid ongoing analyst support following the company's Q2 earnings.

2026. g. 6. aug. 23:02 UTC

News

Relay Therapeutics shares are lower in after-market hours following disappointing Q2 results, including a net loss of $83.7 million and revenue of $350,000.

2026. g. 5. aug. 22:26 UTC

Relay Therapeutics Inc. shares advanced in after-market trading, maintaining a position above its 20-day moving average amid broader macroeconomic sentiment.

2026. g. 4. aug. 19:26 UTC

Correlated Moves

Relay Therapeutics Inc is trading higher during Tuesday's session, continuing its upward trend since Monday's close. Broader market sentiment supports this performance.

2026. g. 3. aug. 21:01 UTC

Relay Therapeutics Inc shares are lower in after-market trading, continuing a downward trend amid three consecutive sessions of declines and no specific news.

2026. g. 31. jūl. 19:16 UTC

Correlated Moves

Relay Therapeutics Inc shares are lower in Friday's session, reflecting broader declines in the biotech sector amid rising yields and inflation concerns.

2026. g. 30. jūl. 17:36 UTC

Correlated Moves
News

Relay Therapeutics Inc is rising as it advances its PI3Kα inhibitor for breast cancer treatment, drawing renewed interest and nearing IPO levels.

2026. g. 29. jūl. 19:36 UTC

Macro Event

Relay Therapeutics Inc shares are higher Wednesday, supported by increased trading volume and recent Federal Reserve decisions on interest rates.

2026. g. 28. jūl. 18:06 UTC

Relay Therapeutics Inc. shares are lower today amid broader market declines, influenced by significant drops in Asian indices and concerns in the semiconductor sector.

2026. g. 27. jūl. 19:56 UTC

Relay Therapeutics Inc. is trading higher, reaching a peak earlier in the session, despite no specific news driving the increase.

2026. g. 22. jūl. 15:46 UTC

Correlated Moves

Relay Therapeutics shares are lower following first-quarter results, which showed a modest decline. The Russell 2000 Index's decrease may also be influencing performance.

2026. g. 21. jūl. 21:51 UTC

Relay Therapeutics Inc shares are higher in after-market trading, reflecting strong momentum amid renewed interest in technology stocks, particularly those related to AI.

2026. g. 20. jūl. 19:16 UTC

Correlated Moves

Relay Therapeutics Inc. is trading lower amid notable volatility, reflecting broader market declines alongside a drop in the ARK Genomic Revolution ETF.

Salīdzinājums

Cenas izmaiņa

Relay Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

41.15% augšup

Prognoze 12 mēnešiem

Vidējais 27.44 USD  41.15%

Augstākais 31 USD

Zemākais 20 USD

Pamatojoties uz 10 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Relay Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

10 ratings

10

Pirkt

0

Turēt

0

Pārdot

Noskaņojums

By Acuity

147 / 340 Rangs Veselības aprūpe

Ziņu noskaņojums

Neutral

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Relay Therapeutics Inc

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
help-icon Live chat